Hey folks  

This is a query targeted at any folks who experience any kind of neuropathic pain for any reason(s), to any degree, and with any frequency, and who've found meds and/or treatment options to reduce, manage, or otherwise cope with the pain.

Please note that we're not asking for ourselves, but for friends who have various forms of this and seem to be having no luck getting decent or timely care through official medical routes 🥺😔

Our own experience of pain has been very different, so we cannot extrapolate anything that has worked for our own issues to neuropathic pain. Relatively-speaking, we've been very fortunate.

We are aware of what the medical organisations say, but we'd much rather hear from folks with personal experiences of any kind, particularly atypical ones that work where others have failed.

As we understand it, commonly-prescribed meds like duloxetine (or any similar SNRI) and gabapentin are often ineffective in many folks, though please correct us if we're wrong there.

We don't have any insight on things like:

Thank you in advance for any answers 🫶  

#NeuropathicPain #disability #disabled #ChronicPain #AskFedi #healthcare #TCA #SNRI #gabapentinoids #gabapentin #pregabalin #neuralgia #meds #GenuinelyAsking #NoReplyGuys

Neuropathic pain - Wikipedia

3 projects by the LED3 researchers Nathaniel Martin, Anthe Janssen and Mirjam Huizenga have been awarded NWO Take-off funding to explore commercial development of compounds and technologies with applications in #oncology, #NeuropathicPain treatment and #kinase research!
https://www.nwo.nl/en/news/49-take-off-projects-awarded-in-spring-round-2025
49 Take-off projects awarded in spring round 2025 | NWO

38 feasibility studies and 11 vroegefasetrajecten have been awarded in the 2025 spring round of Take-off. The Take-off program gives researchers in phase 1 the opportunity to test the feasibility of commercializing their idea based on innovative research results. In phase 2, knowledge-based, innovative start-ups in the early stages of their development receive a loan to get their business off the ground.

NWO

'Spinal Cord DNMT1 Contributes to Diabetic Neuropathic Pain Mediated by miR-152-3p Downregulation' - an article in 'Neuropharmacology and Therapy' on #ScienceOpen:

🔎 https://www.scienceopen.com/hosted-document?doi=10.15212/npt-2024-0008

🖇️ #Neuropharmacology #Epigenetics #DiabetesResearch #NeuropathicPain

Spinal Cord DNMT1 Contributes to Diabetic Neuropathic Pain Mediated by miR-152-3p Downregulation

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d22357388e174">Diabetic neuropathic pain (DNP) is a common complication of diabetes, yet there are no safe and effective therapeutic options. Emerging evidence has indicated that DNA methylation mediated by DNA methyltransferases (DNMTs) is associated with neuropathic pain. However, how DNMTs respond to DNP and the underlying mechanism has not been established. In this study a DNP model was created and DNMT1, but not DNMT3a or DNMT3b, was shown to be upregulated in the spinal cords of mice with DNP. Moreover, DNMT1 was predominantly expressed in spinal cord neurons. Knockdown of DNMT1 in neurons improved nociceptive hypersensitivity in mice with DNP. Furthermore, bioinformatics analysis and real-time quantitative PCR results suggested that downregulated miR-152-3p in the spinal cord of mice with DNP may be an upstream DNMT1 molecule. Overexpression of miR-152-3p reduced DNMT1 expression in the spinal cord and alleviated nociceptive hypersensitivity in mice with DNP. Knockdown of miR-152-3p caused an increase in DNMT1 expression in the spinal cord and induced nociceptive hypersensitivity in naive mice. Moreover, knockdown of DNMT1 reversed miR-152-3p knockdown-induced nociceptive hypersensitivity in naive mice. These results suggest that downregulation of miR-152-3p in the spinal cord is involved in the development of DNP by upregulating DNMT1. These data demonstrate a new mechanism underlying the development of DNP and provide a new therapeutic target for DNP. </p>

ScienceOpen
Time Has No Meaning… Neither Does Life

Time slips by and means Nothing. Days, Weeks, Months and Years just… vanish… into a dim mist of vague dreamlike memories of barely-there Things-That-Happened…I exist barely in any…

DelphineMusic | LeliBug Phoenix
Before you continue to YouTube

Treatment of neuropathic pain with repeated low-dose MDMA: a case report (Gasser, et al, 2025) "This case documents benefits of low doses of MDMA for the treatment of a pain disorder." #mdma #pain #lsd #neuropathicpain #psychedelic #psychedelics #psychedelicresearch https://pubmed.ncbi.nlm.nih.gov/39963333/

Desde el domingo con brote de #EncefalomielitisMiálgica y crisis de dolor neuropático. Al menos hoy duele menos al teclear.

A #MyalgicEncephalomyelitis crash (flare) and neuropathic pain crisis since Sunday. Typing hurts less but still.

#Dolor #DolorNeuropatico #DolorCronico #EMsfc #fibromialgia #Sjögen #Lupus #LES #NeuralgiaDelTrigemino #NdT #Migraña #Pain #ChronicPain #neuropathicPain #ME #MEcfs #fibromyalgia #Sjögrens #SLE #TrigeminalNervePain #TNP #Migraine

Very excited for upcoming conference #NeuPSIG2023. This is the opportunity to get up to date, to learn some translatable skills and pharmacology for animals with #neuropathicpain #animalpainawarenessweek
The underlying mechanism and a potential therapeutic target for neuropathic pain

Neuropathic pain—abnormal hypersensitivity to stimuli—is associated with impaired quality of life and is often poorly managed. Estimates suggest that 3% to 17% of adults suffer from neuropathic pain, including a quarter of people with diabetes and a third of people with HIV.

Medical Xpress

#Covid #NeuropathicPain #神經性疼痛

該發表指出有超過1/3 (34.3%) 的LC患者因神經受損出現無法治癒的廣泛神經性疼痛,有些人在確診後一年出現新的神經性疼痛

評:確診後約有1/5患者有LC (確診越多次越危險),其中又有1/3有神經性疼痛,大量感染導致的影響必須關注

🔗: https://www.mdpi.com/2077-0383/12/4/1672

COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis

Introduction: SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals. Methodology: A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis. Results: The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7–9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3–62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use. Conclusions: Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction.

MDPI